Sign In
Buy NTLA
$12.02
+0.0800 (+0.670%)
At Close: Aug 10, 2026
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial
10:05am, Monday, 02'nd Mar 2026
Intellia Therapeutics Inc. (NASDAQ: NTLA) shares are up on Monday following the FDA's decision to lift the clinical hold on its MAGNITUDE Phase 3 clinical trial.
US FDA lifts clinical hold on Intellia's heart disease gene therapy trial
07:40am, Monday, 02'nd Mar 2026
Intellia Therapeutics said on Monday the U.S. Food and Drug Administration has removed a clinical hold on the late-stage clinical trial for its experimental gene therapy for a heart disease.
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
07:30am, Monday, 02'nd Mar 2026
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
12:15pm, Friday, 27'th Feb 2026
NTLA shares jump after fourth-quarter earnings and revenues exceed expectations. The company focuses on lonvo-z and nex-z pipeline programs.
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
09:47pm, Thursday, 26'th Feb 2026
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
01:16pm, Thursday, 26'th Feb 2026
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to a loss of $1.24 per share a year ago.
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
07:30am, Thursday, 26'th Feb 2026
CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
Intellia Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 24'th Feb 2026
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
What's in Store for These 5 Medical Companies This Earnings Season?
10:11am, Monday, 23'rd Feb 2026
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
Take the Zacks Approach to Beat the Markets: Intellia, Colgate-Palmolive, Getty in Focus
09:06am, Monday, 23'rd Feb 2026
NTLA, CL and GTY are in focus as Zacks highlights strong 12-week gains and post-upgrade rallies across its Focus List and model portfolios.
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
07:30am, Thursday, 19'th Feb 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Hold” by Analysts
04:44am, Monday, 09'th Feb 2026
Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) has earned a consensus recommendation of "Hold" from the twenty-one research firms that are currently covering the firm, Marketbeat reports
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
09:05am, Saturday, 07'th Feb 2026
Intellia Therapeutics recently announced an important regulatory development. The company estimates a large addressable market for its two leading candidates.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 06'th Feb 2026
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
